SMARCD1 is a transcriptional target of specific non-hotspot mutant p53 forms.

Autor: Adduri RSR; Laboratory of Molecular Oncology, Centre for DNA Fingerprinting and Diagnostics, Hyderabad, Telangana, India.; Graduate Studies, Manipal Academy of Higher Education, Manipal, Karnataka, India., George SA; Laboratory of Molecular Oncology, Centre for DNA Fingerprinting and Diagnostics, Hyderabad, Telangana, India.; Graduate Studies, Regional Centre for Biotechnology, Faridabad, Haryana, India., Kavadipula P; Laboratory of Molecular Oncology, Centre for DNA Fingerprinting and Diagnostics, Hyderabad, Telangana, India., Bashyam MD; Laboratory of Molecular Oncology, Centre for DNA Fingerprinting and Diagnostics, Hyderabad, Telangana, India.; Adjunct Faculty, Regional Centre for Biotechnology, Faridabad, Haryana, India.
Jazyk: angličtina
Zdroj: Journal of cellular physiology [J Cell Physiol] 2020 May; Vol. 235 (5), pp. 4559-4570. Date of Electronic Publication: 2019 Oct 21.
DOI: 10.1002/jcp.29332
Abstrakt: Though primarily a tumor suppressor, TP53 harboring specific missense mutations located in the region encoding the DNA binding domain exhibits a gain of function by transcriptional activation of oncogenes. We performed microarray-based messenger RNA profiling of squamous cell carcinoma of the oral tongue (SCCOT) and identified significant elevation of SMARCD1 in samples exhibiting p53 nuclear stabilization. Activation of SMARCD1 by mutant p53 was confirmed by evaluation of additional tongue cancer samples as well as The Cancer Genome Atlas expression datasets. SMARCD1 knockdown in HNSCC cells resulted in a significant reduction in several tumorigenic characteristics including cell viability, ability to form colonies in liquid and solid media and cell migration. We identified significantly increased SMARCD1 transcript levels in tumor versus matched normal samples in SCCOT as well as in other cancer types. Increased SMARCD1 expression predicted poor survival in HNSCC tumors harboring missense p53 mutations. Our results suggest SMARCD1 to be a novel transcriptional target of mutant p53.
(© 2019 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: